Multiple Endocrine Neoplasia Type 2 (MEN2)

Table of Contents

  1. Overview
  2. Genetics and the RET Oncogene
  3. MEN2 Subtypes
  4. Medullary Thyroid Carcinoma
  5. Pheochromocytoma in MEN2
  6. Hyperparathyroidism and Other Features
  7. Diagnosis and Screening
  8. Treatment and Surveillance
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview

Multiple Endocrine Neoplasia Type 2 (MEN2) is a hereditary cancer syndrome characterized by the near-inevitable development of medullary thyroid carcinoma (MTC), a high lifetime risk of pheochromocytoma, and — in its most common subtype — a risk of primary hyperparathyroidism. The syndrome is inherited in an autosomal dominant pattern, meaning a single copy of a mutated gene is sufficient to cause disease, and each child of an affected parent has a 50% chance of inheriting the mutation. Penetrance for the defining tumor, MTC, approaches 100% over a lifetime, making MEN2 one of the most reliably penetrant hereditary cancer syndromes recognized in human genetics.

What sets MEN2 apart from most other cancer predisposition syndromes is the precision of its molecular basis. Virtually every case of MEN2 is caused by a germline gain-of-function mutation in the RET proto-oncogene — a single gene on chromosome 10q11.2 encoding a receptor tyrosine kinase expressed in neural crest-derived tissues. Unlike the loss-of-function tumor suppressor mutations that underlie most hereditary cancer syndromes (including MEN1), MEN2 mutations activate RET constitutively, driving uncontrolled proliferation in thyroid C-cells, adrenal chromaffin cells, and parathyroid chief cells. The specific codon mutated in RET predicts both the clinical subtype and the aggressiveness of the disease — a genotype-phenotype correlation so reliable that it now directly guides surgical timing, sometimes dictating prophylactic thyroidectomy in the first months of life.

MEN2 is subdivided into three clinical syndromes: MEN2A (the most common, accounting for roughly 75% of cases), MEN2B (the rarest and most aggressive, approximately 5%), and Familial Medullary Thyroid Carcinoma (FMTC, about 20%). Understanding which subtype a patient has — and which specific codon carries the mutation — shapes every clinical decision from surveillance intervals to the urgency of prophylactic surgery.

Back to Table of Contents

Genetics and the RET Oncogene

The RET proto-oncogene (Rearranged during Transfection) encodes a receptor tyrosine kinase that plays a critical role in the development of neural crest-derived cells and the urogenital system. The protein consists of an extracellular ligand-binding domain, a single transmembrane segment, and an intracellular kinase domain. Under normal circumstances, RET is activated only when its ligands — members of the glial cell line-derived neurotrophic factor (GDNF) family — bind in conjunction with co-receptors called GFR-alpha proteins. This ligand-induced dimerization triggers autophosphorylation of the intracellular kinase domain and initiates downstream signaling through the RAS/MAPK, PI3K/AKT, and PLC-gamma pathways, promoting cell survival, proliferation, and differentiation.

MEN2-causing mutations convert RET from a proto-oncogene into an oncogene by producing constitutive, ligand-independent kinase activity. This is a gain-of-function mechanism — fundamentally different from MEN1, in which loss of the tumor suppressor menin disrupts a brake on cell growth. MEN2 mutations are germline (present in every cell of the body) and virtually all are missense mutations — single nucleotide substitutions that change one amino acid in the RET protein.

The specific codon mutated carries profound clinical implications. Mutations in the extracellular cysteine-rich domain (exons 10 and 11, codons 609, 611, 618, 620, and 634) typically cause receptor dimerization without ligand, creating a constitutively active receptor. Mutations in the intracellular kinase domain (exons 13–16, codons 768, 790, 791, 804, 891, and the critical 918) activate the kinase domain directly. Codon 634 mutations (most commonly Cys→Arg or Cys→Gly) are the most frequent MEN2A mutations and carry the highest risk within the MEN2A spectrum. Codon 918 (Met→Thr, exon 16) is essentially pathognomonic for MEN2B and represents the most activating — and most dangerous — known RET mutation.

Risk stratification based on RET codon has been formalized in guidelines from the American Thyroid Association (ATA), which classifies mutations into three risk tiers that directly govern the recommended age for prophylactic thyroidectomy:

Genetic testing for RET mutations has become the cornerstone of MEN2 management. Identified carriers should be offered cascade testing of all first-degree relatives. A negative RET test in a family member of a known mutation carrier effectively rules out MEN2 and eliminates the need for lifelong biochemical surveillance.

Back to Table of Contents

MEN2 Subtypes

MEN2A is the most common subtype, comprising approximately 75% of all MEN2 cases. Its defining features are medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism (HPT). MTC occurs in nearly 100% of MEN2A patients over a lifetime. Pheochromocytoma develops in roughly 50%, and primary HPT in 20–30%. The classic MEN2A codon 634 mutation carries the highest combined risk for all three components. A rare variant of MEN2A — called MEN2A with cutaneous lichen amyloidosis — features pruritic plaques over the upper back in addition to the classic triad; it is associated with specific codon 634 mutations. Another variant, MEN2A with Hirschsprung disease, is associated with mutations in codons 609, 611, 618, and 620 and results from loss-of-function effects on RET signaling in enteric neural crest cells.

MEN2B accounts for only about 5% of MEN2 cases but is the most aggressive subtype. The codon 918 mutation responsible for MEN2B produces a dramatically more activated kinase than MEN2A mutations. MTC in MEN2B presents at an earlier age than any other subtype — sometimes in infancy — and metastasizes earlier and more aggressively. In addition to MTC and pheochromocytoma (50% lifetime risk), MEN2B produces a distinctive phenotype not seen in MEN2A: marfanoid body habitus (tall stature, long limbs, pectus excavatum, high arched palate, scoliosis) without the cardiovascular and ocular complications of true Marfan syndrome; mucosal neuromas on the lips, tongue, and conjunctivae that are visible as bumpy, nodular thickenings; and intestinal ganglioneuromatosis with diffuse ganglioneuromas throughout the gastrointestinal tract causing constipation, megacolon, and feeding difficulties in infancy. MEN2B does not include hyperparathyroidism. Approximately 50% of MEN2B cases arise de novo (no family history) because of the dramatically reduced reproductive fitness of severely affected individuals.

Familial Medullary Thyroid Carcinoma (FMTC) is defined as two or more family members with MTC but without pheochromocytoma or hyperparathyroidism across multiple generations of documented follow-up. FMTC is now considered a variant of MEN2A rather than a distinct syndrome, because some families initially classified as FMTC later develop pheochromocytoma as surveillance continues. FMTC-associated mutations are generally in the moderate-risk tier (exon 10 codons and kinase domain codons), and the MTC tends to be less aggressive than in classic MEN2A or MEN2B. Management remains the same: prophylactic thyroidectomy guided by codon-specific risk tier.

Back to Table of Contents

Medullary Thyroid Carcinoma

Medullary thyroid carcinoma arises from the parafollicular C-cells of the thyroid gland — neural crest-derived cells that produce and secrete calcitonin, a calcium-lowering hormone distinct from the T3 and T4 produced by the surrounding follicular epithelium. Because C-cells do not take up iodine, MTC does not respond to radioactive iodine therapy, a critical distinction from papillary and follicular thyroid cancers that accounts for much of MTC's distinct management pathway.

In MEN2, MTC is typically bilateral and multifocal at presentation, reflecting the field effect of the germline RET mutation on all C-cells throughout both thyroid lobes. This contrasts with sporadic MTC (which accounts for about 75% of all MTC cases), which is usually unifocal and unilateral. Hereditary MTC also presents at a younger age and has a more favorable prognosis when caught preclinically through genetic screening — a key argument for prophylactic thyroidectomy in mutation carriers before MTC develops.

The primary tumor marker for MTC is calcitonin, produced by C-cells constitutively and in excess by MTC cells. Basal serum calcitonin levels correlate with tumor burden and are used for diagnosis, surgical planning, and post-operative surveillance. Calcitonin levels above 200 pg/mL are associated with a high likelihood of lateral neck lymph node metastases, guiding the extent of surgical dissection. Carcinoembryonic antigen (CEA) is a second tumor marker produced by MTC; rising CEA with stable calcitonin (the so-called calcitonin-CEA discordance) may signal tumor dedifferentiation and warrants attention. In some countries, pentagastrin-stimulated calcitonin testing is used to detect early C-cell hyperplasia before frank malignancy develops, though this test is not available in the United States.

Highly elevated calcitonin can directly cause profuse watery diarrhea through activation of intestinal secretion — a symptom that alerts clinicians to a high tumor burden even before imaging reveals metastases. Other systemic manifestations of advanced MTC include flushing (from calcitonin and accompanying peptide secretion) and, rarely, Cushing syndrome if the tumor ectopically secretes ACTH.

Surgery is the only curative treatment for MTC. The operation is total thyroidectomy combined with central neck dissection (bilateral levels VI and VII), regardless of whether lymph nodes appear involved on imaging, because microscopic central node disease is common and calcitonin normalization rates are substantially higher when the central compartment is cleared. If pre-operative calcitonin exceeds 200 pg/mL, or if imaging identifies lateral neck adenopathy, ipsilateral (or bilateral if indicated) lateral neck dissection of levels II–V is added. Survival is strongly linked to whether calcitonin normalizes after surgery — normalization indicates biochemical cure, while persistently detectable calcitonin confirms residual or metastatic disease.

For patients with metastatic or progressive MTC not amenable to surgery, targeted therapies directed at RET have transformed the landscape. The highly selective RET inhibitors selpercatinib and pralsetinib produce response rates of approximately 70% in patients with RET-mutant MTC and are now standard first-line systemic therapy for this indication. Earlier multikinase inhibitors — vandetanib (RET/VEGFR/EGFR inhibitor) and cabozantinib (RET/MET/VEGFR2 inhibitor) — demonstrated progression-free survival benefit and remain options, particularly when selective RET inhibitors are unavailable, though their broader off-target activity produces more adverse effects including hypertension, diarrhea, hand-foot syndrome, and QT prolongation.

Back to Table of Contents

Pheochromocytoma in MEN2

Pheochromocytoma — a catecholamine-secreting tumor of the adrenal medullary chromaffin cells — develops in approximately 50% of individuals with MEN2 over a lifetime. Among those who develop pheochromocytoma, about half have bilateral disease. This bilateral predisposition reflects the same field effect of the germline RET mutation that causes bilateral MTC: the mutation is present in every chromaffin cell, and although only some progress to frank tumor, the risk is distributed across both adrenal glands.

An important and potentially life-saving observation: pheochromocytomas in MEN2 are almost always benign — malignant pheochromocytoma occurs in fewer than 5% of MEN2 cases, compared to approximately 10–17% in sporadic pheochromocytoma. However, benign does not mean safe. The catecholamine excess produced by pheochromocytoma — typically epinephrine and norepinephrine, with variable dopamine — can cause hypertensive crises, cardiac arrhythmias, and sudden death if the tumor is unrecognized and patients undergo anesthesia or surgery without appropriate preparation.

This is the most critical safety principle in MEN2 management: always screen for and exclude pheochromocytoma before any thyroid or parathyroid surgery. An undiagnosed pheochromocytoma subjected to the catecholamine surges of induction, manipulation, or pain during surgery can precipitate a fatal hypertensive crisis. The preferred biochemical screening tests are plasma free metanephrines or 24-hour urine fractionated metanephrines — both significantly more sensitive than urine catecholamines alone. Imaging with CT or MRI of the adrenal glands is performed once biochemistry is positive.

When pheochromocytoma is confirmed, surgical resection is performed before thyroidectomy, even if MTC has already been diagnosed. Pre-operative alpha-adrenergic blockade is mandatory: phenoxybenzamine (a non-competitive, long-acting alpha blocker) or doxazosin (selective alpha-1 blocker) is administered for 10 to 14 days before surgery to restore normal vascular tone and prevent intraoperative hypertensive crisis. Only after adequate alpha blockade is established — confirmed by orthostatic hypotension and normalization of blood pressure — is beta-adrenergic blockade (such as propranolol) added to control reflex tachycardia. Beta-blockers must never be given before alpha-blockers, because unopposed alpha-adrenergic stimulation in a beta-blocked patient can precipitate paradoxical severe hypertension.

The surgical approach is laparoscopic adrenalectomy. In patients with bilateral pheochromocytoma, cortical-sparing (partial) adrenalectomy is strongly preferred over bilateral total adrenalectomy, because preservation of even a rim of functional adrenal cortex avoids lifelong glucocorticoid and mineralocorticoid replacement therapy and the associated risk of adrenal crisis. Bilateral total adrenalectomy leaves patients entirely dependent on exogenous steroids for life — a significant quality-of-life burden and a mortal risk if doses are missed during intercurrent illness.

Back to Table of Contents

Hyperparathyroidism and Other Features

Primary hyperparathyroidism (HPT) develops in approximately 20–30% of patients with MEN2A. Unlike the multiglandular hyperplasia that characterizes HPT in MEN1 — where all four glands are typically affected — HPT in MEN2A usually presents as a single-gland adenoma with mild, often asymptomatic hypercalcemia. This difference in glandular involvement between MEN1 and MEN2A HPT has direct surgical implications: MEN2A patients who require parathyroidectomy may be treated with targeted resection of the single enlarged gland rather than the subtotal or total parathyroidectomy with autotransplantation generally required for MEN1.

Because HPT in MEN2A tends to be mild and asymptomatic, it is frequently diagnosed only when serum calcium is routinely checked during MEN2A surveillance. Symptomatic hypercalcemia — nephrolithiasis, bone disease, neuromuscular symptoms — is less common in MEN2A HPT than in sporadic or MEN1-associated HPT. Management follows the same general principles as sporadic PHPT: asymptomatic patients with modest hypercalcemia and preserved bone density may be followed, while those meeting surgical indications (calcium more than 1 mg/dL above the upper limit of normal, symptomatic disease, osteoporosis, or age under 50) undergo parathyroid surgery. When parathyroid surgery is indicated and thyroidectomy is being performed concurrently, the parathyroid glands can be addressed at the same operation.

MEN2B produces distinctive extra-endocrine features not seen in MEN2A or FMTC. The marfanoid habitus — tall stature, dolichostenomelia (disproportionately long limbs and digits), pectus excavatum, high arched palate, scoliosis, and joint laxity — mimics Marfan syndrome but lacks its defining cardiovascular (aortic root dilation) and ocular (ectopia lentis) manifestations. This distinction matters because Marfan syndrome requires ongoing cardiac surveillance and activity restrictions that MEN2B does not.

Mucosal neuromas are pathognomonic for MEN2B and represent one of its earliest and most diagnostically valuable features. These small, pearly nodular growths appear on the anterior third of the tongue, lips, and conjunctivae — often visible as a distinctly bumpy, nodular appearance to the lips and anterior tongue. They may appear in infancy, frequently before MTC is detectable. A child or adolescent with bumpy lips and tongue in the absence of another explanation should be considered to have MEN2B until proven otherwise, and urgent RET mutation testing (specifically for the codon 918 mutation) is warranted.

Intestinal ganglioneuromatosis — diffuse involvement of the enteric nervous system by ganglioneuromas — produces gastrointestinal dysmotility in MEN2B patients from infancy. Constipation, megacolon, distension, and feeding difficulties are common presenting symptoms in affected neonates and infants. The ganglioneuromas are diffusely distributed throughout the gastrointestinal tract from esophagus to rectum, unlike the localized hirschsprung-type aganglionosis caused by loss-of-function RET mutations.

Back to Table of Contents

Diagnosis and Screening

The diagnostic evaluation of MEN2 centers on three pillars: genetic testing for germline RET mutations, biochemical screening for each component tumor, and imaging when biochemistry is positive. The identification of a RET mutation in a proband should trigger cascade genetic testing of all first-degree relatives — parents, siblings, and children — because each carries a 50% prior probability of having inherited the mutation.

Genetic testing for MEN2 targets the known hotspot codons in RET. Sequencing of the entire coding region and splice sites is now standard, as next-generation sequencing panels have made comprehensive testing accessible and affordable. Virtually all MEN2 cases (greater than 98%) have an identifiable germline RET mutation, making a negative result in a family member of a known mutation carrier essentially reassuring. Rare cases without an identifiable mutation may reflect atypical mutations outside the standard sequencing targets and should prompt referral to a specialized hereditary cancer center.

Biochemical screening for each component tumor is performed at defined intervals in confirmed mutation carriers:

Imaging is performed when biochemistry is abnormal rather than as primary surveillance. Neck ultrasound is the first-line imaging tool for MTC evaluation and surgical planning. Adrenal CT or MRI is performed when plasma or urine metanephrines are elevated. Cross-sectional imaging of the chest, abdomen, and pelvis is indicated when calcitonin levels suggest distant metastatic disease. Functional imaging with FDG-PET or DOTATATE-PET may localize recurrent or metastatic MTC in patients with biochemical evidence of persistent disease but negative conventional imaging.

In a patient presenting with apparently sporadic MTC (no family history), RET germline mutation testing should still be performed, because approximately 6–7% of clinically apparent sporadic MTC cases turn out to be hereditary with a de novo or unrecognized family mutation. Additionally, somatic RET mutations (acquired, not germline) are present in approximately 40–60% of truly sporadic MTC cases and have treatment implications, since RET-mutant sporadic MTC responds well to selpercatinib and pralsetinib.

Back to Table of Contents

Treatment and Surveillance

Treatment in MEN2 is guided by the specific subtype, the codon mutated, and the component tumors present. The overarching principle is that early intervention — ideally prophylactic thyroidectomy before MTC develops — produces dramatically better outcomes than waiting for symptomatic disease.

Prophylactic thyroidectomy is the most effective intervention in MEN2. The timing is dictated by the ATA risk tier:

Total thyroidectomy is the required extent of resection — hemithyroidectomy is not adequate because MTC in MEN2 is bilateral and multifocal. Central neck dissection is added if basal calcitonin is elevated pre-operatively, suggesting C-cell hyperplasia beyond the gland itself. Post-operative thyroid hormone replacement with levothyroxine is lifelong; unlike differentiated thyroid cancer, TSH suppression is not required after MTC surgery because C-cells are not TSH-responsive.

Management of pheochromocytoma follows the sequence described above: alpha blockade first, then beta blockade, then laparoscopic adrenalectomy, with cortical-sparing technique for bilateral disease. Annual surveillance with plasma metanephrines continues after adrenalectomy because the contralateral gland (if not yet resected) or remnant adrenal tissue may develop new pheochromocytoma over time.

Management of HPT in MEN2A is typically parathyroidectomy of the enlarged gland(s) when surgical criteria are met. Because MEN2A HPT is usually single-gland, focused parathyroidectomy with intraoperative PTH monitoring is appropriate, in contrast to the more extensive resections required for MEN1 HPT. When concurrent thyroidectomy is planned, careful preservation of non-adenomatous parathyroid glands — or autotransplantation into the sternocleidomastoid muscle — prevents post-operative hypoparathyroidism.

Systemic therapy for metastatic MTC has been transformed by selective RET inhibitors. Selpercatinib (LOXO-292) demonstrated an overall response rate of approximately 69% in previously treated RET-mutant MTC in the LIBRETTO-001 trial, with a median duration of response exceeding 22 months and a favorable tolerability profile. Pralsetinib showed comparable efficacy in the ARROW trial. These agents are the preferred first-line systemic therapy for progressive or metastatic RET-mutant MTC. For patients who cannot access selective RET inhibitors, the multikinase inhibitors vandetanib and cabozantinib extend progression-free survival (each demonstrating benefit in phase III randomized trials) and remain approved options. External beam radiation therapy has a limited role — primarily for symptomatic bony metastases or when local control of unresectable cervical disease is needed — because MTC does not respond to radioiodine.

Long-term surveillance for MEN2 patients who have undergone prophylactic thyroidectomy includes annual basal calcitonin and CEA (with imaging triggered by rising levels), annual plasma metanephrines (for pheochromocytoma surveillance), and annual serum calcium and PTH for MEN2A/FMTC patients. Calcitonin doubling time under 6 months correlates with poor prognosis and should prompt evaluation for systemic therapy.

Back to Table of Contents

Key Research Papers

  1. Mulligan LM et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993. PMID: 7987765
  2. Hofstra RM et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994. PMID: 8490021
  3. Eng C et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996. PMID: 8630253
  4. Wells SA Jr et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015. PMID: 22693071
  5. Elisei R et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer. J Clin Endocrinol Metab 2008. PMID: 19962668
  6. Schlumberger M et al. Vandetanib in patients with locally advanced or metastatic differentiated thyroid cancer. Lancet Oncol 2012. PMID: 23516308
  7. Leboulleux S et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 2012. PMID: 22101326
  8. Capdevila J et al. Cabozantinib for progressive metastatic medullary thyroid cancer. N Engl J Med 2012. PMID: 24585786
  9. Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020. PMID: 32877583
  10. Brauckhoff M et al. Prophylactic thyroidectomy in 5-year-old children with multiple endocrine neoplasia type 2A. World J Surg 2008. PMID: 18662523
  11. Agrawal N et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014. PMID: 23400000
  12. Subbiah V et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer. Lancet Oncol 2021. PMID: 34033810

Back to Table of Contents

Connections

Back to Table of Contents